Page 637 - Traité de Chimie Thérapeutique 4 Médicaments en relation avec des systèmes hormonaux

M LES ANTI-ANDROGÈNES 597

BLOM J.H.M. et al. Pharmacokinetics and endocrine effects of the LH RH analogue
buserelin after subcutaneous implantation of a slow release préparation in prostatic
cancer patients. Urological research, 1989,17, 43-46.
BOCCARDO F. et al. Goserelin acetate with or without flutamide in the treatment of
patients with locally advanced or metastatic prostate cancer. Eur. J. Cancer, 1993,
29 A, (8), 1088-1093.
BRESSLER LR. et al. Use of clonidine to treat hot flashes secondary to leuprolide or
goserelin. Am. Pharmacother., 1993, 27 (2), 182-185.
BRUCHOVSKY N. et al. Luteinizing hormone-releasing hormone agonists in prostate
cancer. Elimination of flare reaction by pretreatment with cyprotérone acetate and
low dose diéthylstilbestrol. Cancer, 1993, 72 (5), 1685-1691.
DECENSI A. et al. Long term endocrine effects of administration of either a non-steroi-
dal antiandrogen or a luteinizing hormone. Releasing hormone agonist in men with
prostate cancer. Acta Endocrinologica, 1993,129, 315-321.
DENIS L.J. et al. Goserelin acetate and flutamide versus bilateral orchiectomy : a
phase III EORTC Trial (30853). Urology, 1993, 42 (2), 119-130.
ERI L.M. et al. A prospective, placebo-controlled study of the luteinizing hormone-
releasing hormone agonist leuprolide as treatment for patients with benign prostatic
hyperplasie. The Journal of Urology, 1993,150, 359-364.
HAEFLIGER J.M. Etude randomisée comparant Zoladex versus Zoladex + flutamide
dans le traitement du cancer avancé de la prostate. Helv. Chir. Acta, 1992, 59, 477­
483.
HAMPSON S.J. et al. LH RH Analogues as primary treatment for urinary rétention in
patients with prostatic carcinoma. British Journal of Urology, 1993, 71, 583-586.
HUBEN R.P. Hormone therapy of prostatic bone métastasés. Adv. Exp. Med. Biol.,
1992, 324, 305-316.
SANDOW J. et al. Pharmacokinetics and endocrine effects of slow release formula­
tions of LH RH analogues. J. Steroid. Biochem. Molec. Biol., 1990, 37 (6), 925-931.
SCHALLY A.V. et al. Présent status of agonistic and antagoniste analogs of LH RH in
the treatment of advanced prostate cancer. Biomed. & Pharmacother., 1992, 46,
465-471.